RELB and myeloid sarcoma: In MS and its animal model EAE, RelB exerts an impact on Th17, Th1, γδT17, steady-state migratory DCs, DCs, B cells, macrophages, microglia, oligodendrocytes and astrocytes, which provide the theoretic foundation for possible therapies that target RelB.